Galapagos to hold Annual R&D Update 2017 on 20 June
(Thomson Reuters ONE) -
Mechelen, Belgium; 17 May 2017; 7.30 CET - Galapagos NV (Euronext & NASDAQ:
GLPG) announces it will hold its Annual R&D Update 2017 on 20 June at 8 AM EDT
at the Yale Club in New York City. This event will also be webcast.
Each year, Galapagos presents its progress in discovering and developing
therapies with novel modes of action to shareholders, investors, banks, and the
media. This year's event will feature updates on selective JAK1 inhibitor
filgotinib, currently in multiple Phase 2 and Phase 3 studies, and on the triple
combination therapy development in cystic fibrosis. Galapagos will further
highlight progress in its other partnered and proprietary programs, including
earlier stage assets moving forward.
Please RSVP to susan(at)sanoonan.com to reserve your place at breakfast starting at
7:30 AM EDT/13.30 CET at the Yale Club, 50 Vanderbilt Ave, NY on 20 June 2017.
The event also will be webcast starting at 8 AM EDT/14.00 CET, to be accessed
via www.glpg.com.
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises Phase 3, Phase 2, Phase 1, pre-
clinical, and discovery programs in cystic fibrosis, inflammation, fibrosis,
osteoarthritis and other indications. We have discovered and developed
filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 530 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More information at www.glpg.com.
Contacts
Investors: Media:
Elizabeth Goodwin Evelyn Fox
VP IR & Corporate Communications Director Communications
+1 781 460 1784 +31 6 53 591 999
communications(at)glpg.com
Paul van der Horst
Director IR & Business Development
+31 6 53 725 199
ir(at)glpg.com
Forward-looking statements
This release may contain forward-looking statements, including statements
regarding Galapagos' strategic ambitions, the anticipated timing of clinical
studies with product candidates and the progress and results of such studies.
Galapagos cautions the reader that forward-looking statements are not guarantees
of future performance. Forward-looking statements involve known and unknown
risks, uncertainties and other factors which might cause the actual results,
financial condition and liquidity, performance or achievements of Galapagos, or
industry results, to be materially different from any historic or future
results, financial conditions and liquidity, performance or achievements
expressed or implied by such forward-looking statements. In addition, even if
Galapagos' results, performance, financial condition and liquidity, and the
development of the industry in which it operates are consistent with such
forward-looking statements, they may not be predictive of results or
developments in future periods. Among the factors that may result in differences
are the inherent uncertainties associated with competitive developments,
clinical trial and product development activities and regulatory approval
requirements (including that data from the ongoing and planned clinical research
programs may not support registration or further development of product
candidates due to safety, efficacy or other reasons), Galapagos' reliance on
collaborations with third parties (including its collaboration partner for
filgotinib, Gilead, and with its collaboration partner for cystic fibrosis,
AbbVie), and estimating the commercial potential of Galapagos' product
candidates. A further list and description of these risks, uncertainties and
other risks can be found in Galapagos' Securities and Exchange Commission (SEC)
filings and reports, including in Galapagos' most recent annual report on form
20-F filed with the SEC and subsequent filings and reports filed by Galapagos
with the SEC. Given these uncertainties, the reader is advised not to place any
undue reliance on such forward-looking statements. These forward-looking
statements speak only as of the date of publication of this document. Galapagos
expressly disclaims any obligation to update any such forward-looking statements
in this document to reflect any change in its expectations with regard thereto
or any change in events, conditions or circumstances on which any such statement
is based or that may affect the likelihood that actual results will differ from
those set forth in the forward-looking statements, unless specifically required
by law or regulation.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 17.05.2017 - 07:30 Uhr
Sprache: Deutsch
News-ID 543741
Anzahl Zeichen: 6012
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 184 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Galapagos to hold Annual R&D Update 2017 on 20 June"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
